scout
|Videos|June 6, 2017

Dr. von Minckwitz on Phase III Results of the APHINITY Trial for Breast Cancer

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the phase III results of the APHINITY trial, which explored the addition of pertuzumab (Perjeta) to standard postoperative trastuzumab (Herceptin) therapy for patients with HER2-positive early breast cancer.

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the phase III results of the APHINITY trial, which explored the addition of pertuzumab (Perjeta) to standard postoperative trastuzumab (Herceptin) therapy for patients with HER2-positive early breast cancer.

<<<

View more from the 2017 ASCO Annual Meeting

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME